Long-Term Treatment of Central Precocious Puberty with a Long-Acting Analogue of Luteinizing Hormone Release Hormone (D-Tryp6-GnRH) in Monthly Injections

1993 ◽  
Vol 25 (02) ◽  
pp. 105-109 ◽  
Author(s):  
J. A. M. Marcondes ◽  
A. Abujamra ◽  
S. Minanni ◽  
B. Mendonca ◽  
M. Nery ◽  
...  
Keyword(s):  
Luteinizing Hormone ◽  
Precocious Puberty ◽  
Central Precocious Puberty ◽  
Term Treatment ◽  
Hormone Release ◽  
Luteinizing Hormone Release Hormone ◽  
Luteinizing Hormone Release ◽  
Long Term Treatment ◽  
Long Acting

Long-Term Treatment of Central Precocious Puberty with a Long-Acting Analogue of Luteinizing Hormone-Releasing Hormone

1983 ◽  
Vol 309 (21) ◽  
pp. 1286-1290 ◽  
Author(s):  
M.Joan Mansfield ◽  
Donna E. Beardsworth ◽  
Jacquelyn S. Loughlin ◽  
John D. Crawford ◽  
Hans H. Bode ◽  
...  
Keyword(s):  
Luteinizing Hormone ◽  
Precocious Puberty ◽  
Central Precocious Puberty ◽  
Term Treatment ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Long Term Treatment ◽  
Long Acting

scholarly journals Final height in central precocious puberty after long term treatment with a slow release GnRH agonist.

1996 ◽  
Vol 75 (4) ◽  
pp. 292-297 ◽  
Author(s):  
W Oostdijk ◽  
B Rikken ◽  
S Schreuder ◽  
B Otten ◽  
R Odink ◽  
...  
Keyword(s):  
Precocious Puberty ◽  
Gnrh Agonist ◽  
Slow Release ◽  
Final Height ◽  
Central Precocious Puberty ◽  
Term Treatment ◽  
Long Term Treatment

Sustained drug delivery optimizes long-term treatment of patients with schizophrenia

2004 ◽  
Vol 16 (6) ◽  
pp. 319-325 ◽  
Author(s):  
Pierre S. Chue ◽  
Peter D'Hoore ◽  
J. Michael Ramstack
Keyword(s):  
Antipsychotic Agents ◽  
Term Treatment ◽  
Treatment Programs ◽  
Sustained Drug Delivery ◽  
Partial Compliance ◽  
Long Term Treatment ◽  
Optimal Maintenance ◽  
Long Acting ◽  
The Impact

Chronic disorders such as schizophrenia require long-term treatment programs in order to maintain patients at the lowest level of symptomatology, reduce the likelihood of psychotic relapse, and support achievement of remission and recovery. Evidence suggests that treatment with long-acting injectable antipsychotics reduces the impact of partial compliance and provides predictable release of medication, assuring continuous therapeutic coverage. Until recently, only conventional antipsychotic agents were available in long-acting formulations, thereby foregoing the advantages of the atypical class. Atypical agents which are given orally have been shown to provide long-term efficacy and tolerability benefits compared with conventional agents, but are limited by the need for daily administration. The most recent pharmacological strategy to achieve optimal maintenance treatment has been to combine the benefits of an atypical antipsychotic with delivery in a water-based long-acting formulation. The first antipsychotic to achieve this combination – long-acting risperidone – may thus represent an important advance in the optimization of long-term treatment outcomes in patients with schizophrenia.

Sign in / Sign up

Export Citation Format

Share Document